Track the Mountain Crest Acquisition Corp. III share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mountain Crest Acquisition Corp. III has logged 18 insider filings. The latest transaction was filed on 22 February 2023 (J). Among the most active insiders: Mountain Crest Holdings III LLC. All data is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
18 of 18 declarations
Mountain Crest Acquisition Corp. III is a special purpose acquisition company (SPAC), meaning it was created as a listed cash shell to pursue a merger, share exchange, asset acquisition, or similar business combination. For French-speaking investors evaluating the name MCAEU, the key point is that this is not a traditional operating company with an established product portfolio; its business model is to raise capital in the public markets and then identify and complete a transaction with a private target. Mountain Crest Acquisition Corp. III was set up within that framework, with a principal executive office historically disclosed in New York, United States, at 311 West 43rd Street, 12th Floor, New York, NY 10036. It was associated with the NASDAQ market under the MCAE/MCAEU symbols, placing it squarely in the U.S. SPAC financing ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1859035/000182912623004491/mountaincrest5_pre14a.htm?utm_source=openai)) Historically, Mountain Crest Acquisition Corp. III belonged to a broader family of Mountain Crest-sponsored SPAC vehicles. As with most SPACs, the company was formed for a finite purpose and operated under a deadline to complete a business combination. In February 2023, it announced the closing of its merger with ETAO International Group, a digital healthcare group described as providing medical care through biomedical and AI-enabled technologies, primarily focused on patients in China. That transaction is central to the company’s investment story, because it shows that MCAEU’s role was to serve as the public-market acquisition vehicle rather than to develop a proprietary operating business. Following the transaction, the securities of the combined company were slated to trade under a different name and ticker on NASDAQ. ([nasdaq.com](https://www.nasdaq.com/press-release/mountain-crest-acquisition-corp.-iii-closes-its-business-combination-with-etao?utm_source=openai)) From a business-line standpoint, Mountain Crest Acquisition Corp. III’s “products” are really SPAC services: sourcing a target, negotiating a transaction, structuring the deal, and taking the combined company public. Its competitive position should be understood relative to other SPAC sponsors, where success depends on sponsor credibility, execution speed, capital markets access, and the ability to find a credible target within the required timeline. There is no conventional operating moat comparable to a manufacturing or software company; instead, the value proposition lies in financial structuring and deal execution. For recent developments, the most notable items are the completed business combination in 2023 and SEC filings such as Form 4 insider ownership disclosures, which are typical for issuers with active corporate-action histories. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1853775/000090266423001976/xslF345X03/ownership.xml?utm_source=openai)) In short, Mountain Crest Acquisition Corp. III should be viewed as a U.S.-listed NASDAQ SPAC from the United States, with its historical significance tied to its merger activity rather than to a standalone operating franchise.